Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of sorafenib in advanced hepatocellular carcinoma with Child-Pugh B
2008-008232-87Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC) and Cirrhosis, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Proportion of patients with grade ≥3 drug-related toxicity. Started Mar 2009; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on 2008-008232-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008232-87.